Biotechnology Private UK-based cell and gene therapy company Ixaka, previously known as Rexgenero, has announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product. 8 March 2022